VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. This matters because it addresses growing regulatory and ethical pressures to minimize animal use while maintaining scientific rigor, and it could set a precedent for how biotechnology companies integrate alternative methods into drug development.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications are significant for investors and the broader biotech industry. By reducing reliance on animal studies, VERAXA could bring therapies to clinic faster and at lower cost, potentially improving its competitive position. The FDA has been encouraging NAMs as part of its modernization efforts, and companies that successfully integrate these methods may benefit from smoother regulatory interactions. For VERAXA, this update underscores its commitment to innovation not only in drug design but also in development processes. To view the full press release, visit https://ibn.fm/9YRJw.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
Investors can stay updated on the latest news and updates relating to VRXA in the company's newsroom at http://ibn.fm/VRXA. The announcement was disseminated through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, BioMedWire brings its clients unparalleled recognition and brand awareness. BioMedWire is where breaking news, insightful content, and actionable information converge. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BioMedWire, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
